Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Dry eye syndrome.

BIBLIOGRAPHIC SOURCE(S)

  • American Academy of Ophthalmology Cornea/External Disease Panel, Preferred Practice Patterns Committee. Dry eye syndrome. San Francisco (CA): American Academy of Ophthalmology (AAO); 2003. 21 p. [75 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: American Academy of Ophthalmology (AAO), Preferred Practice Patterns Committee, Cornea/External Disease. Dry eye syndrome. San Francisco (CA): American Academy of Ophthalmology (AAO); 1998. 18 p.

All Preferred Practice Patterns are reviewed by their parent panel annually or earlier if developments warrant.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The ratings of importance to the care process (A, B, C) and the ratings of strength of evidence (I, II, III) are defined at the end of the "Major Recommendations" field.

Diagnosis

The initial evaluation of a patient who presents with symptoms suggestive of dry eye should include those features of the comprehensive adult medical eye evaluation relevant to dry eye. [A:III]

Patient History

  • Symptoms and signs [A:III]
  • Exacerbating conditions [B:III]
  • Duration of symptoms [A:III]
  • Topical medications used and their effect on symptoms [A:III]

The ocular history may include details about the following:

  • Contact lens wear, schedule, and care [A:III]
  • Allergic conjunctivitis [B:III]
  • Corneal history [A:III]
  • Punctal surgery [A:III]
  • Eyelid surgery [A:III]
  • Bell's palsy [A:III]
  • Chronic ocular surface inflammation [A:III]

The medical history takes into account the following elements:

  • Smoking [A:III]
  • Dermatological diseases [A:III]
  • Atopy [A:III]
  • Menopause [A:III]
  • Systemic inflammatory diseases [A:III]
  • Systemic medications [A:III]
  • Trauma [B:III]
  • Chronic viral infections [B:III]
  • Surgery [B:III]
  • Radiation of orbit [B:III]
  • Neurological conditions [B:III]
  • Dry mouth, dental cavities, oral ulcers [B:III]

Examination

The physical examination includes a visual acuity measurement, [A:III] an external examination, [A:III] and slit-lamp biomicroscopy. [A:III]

The external examination should pay particular attention to the following:

  • Skin [A:III]
  • Eyelids [A:III]
  • Adnexa [A:III]
  • Proptosis [B:III]
  • Cranial nerve function [A:III]
  • Hands [B:III]

The slit-lamp biomicroscopy should focus on the following parts of the eye:

  • Tear film [A:III]
  • Eyelashes [A:III]
  • Anterior and posterior eyelid margins [A:III]
  • Puncta [A:III]
  • Inferior fornix and tarsal conjunctiva [A:III]
  • Cornea [A:III]

Diagnostic Tests

For patients with moderate to severe aqueous tear deficiency, the diagnosis can be made by using one or more of the following tests: tear break-up time test, ocular surface dye staining pattern (rose bengal, fluorescein, or lissamine green), and the Schirmer test. Corneal sensation should be assessed when trigeminal nerve dysfunction is suspected. [A:III] A laboratory and clinical evaluation for autoimmune disorders should be considered for patients with significant dry eyes, other signs and symptoms of an autoimmune disorder (e.g., dry mouth), or a family history of an autoimmune disorder. [A:III]

Treatment

For patients with aqueous tear deficiency, the following measures are appropriate: [A:III]

  • Elimination of exacerbating medications where feasible
  • Ocular environmental interventions
  • Computer work site interventions
  • Aqueous tear enhancement with topical agents or external means
  • Medications
  • Correction of the lid abnormality
  • Punctal occlusion or tarsorrhaphy for severe cases

Follow-up

The frequency and extent of the follow-up evaluation will depend on the severity of disease, the therapeutic approach, and response to the therapy. Patients with sterile corneal ulceration associated with dry eye require careful monitoring, sometimes on a daily basis. [A:III]

Provider and Setting

Because dry eye can be associated with systemic immunological disorders and use of systemic medications, broad medical skills and training are important for appropriate diagnosis and management. Patients with dry eye who are evaluated by non-ophthalmologist health care providers should be referred promptly to the ophthalmologist if any of the following occurs: [A:III]

  • Visual loss
  • Moderate or severe pain
  • Lack of response to the therapy
  • Corneal ulceration

Counseling/Referral

The most important aspects of caring for patients with dry eye are to educate them about the chronic nature of the disease process and to provide specific instructions for therapeutic regimens. It is helpful to reassess periodically the patient's compliance and understanding of the disease, the risks for associated structural changes, and to re-inform the patient as necessary.

For patients with irreversible tear deficiency or evaporative increase associated with chronic conditions such as blepharitis, the ophthalmologist should educate the patient about the natural history and chronic nature of dry eye. [A:III] Patients with pre-existing dry eye should be cautioned that laser in situ keratomileusis or photorefractive keratectomy may worsen their dry eye condition. [A:III]

In moderate to severe cases that are unresponsive to treatment or when systemic disease is suspected, timely referral to an ophthalmologist who is knowledgeable and experienced in the management of these entities is recommended. [A:III] Patients with systemic disease such as primary Sjögren syndrome, secondary Sjögren (associated with a connective tissue disease), or connective tissue disease such as rheumatoid arthritis should be managed by an appropriate medical specialist. [A:III]

Definitions:

Ratings of importance to care process

Level A, most important
Level B, moderately important
Level C, relevant but not critical

Ratings of strength of evidence

  1. Level I includes evidence obtained from at least one properly conducted, well-designed randomized, controlled trial. It could include meta-analyses of randomized controlled trials.
  2. Level II includes evidence obtained from the following:
    • Well-designed controlled trials without randomization
    • Well-designed cohort or case-control analytic studies, preferably from more than one center
    • Multiple-time series with or without the intervention
  3. Level III includes evidence obtained from one of the following:
    • Descriptive studies
    • Case reports
    • Reports of expert committees/organization
    • Expert opinion (e.g., Preferred Practice Pattern panel consensus)

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • American Academy of Ophthalmology Cornea/External Disease Panel, Preferred Practice Patterns Committee. Dry eye syndrome. San Francisco (CA): American Academy of Ophthalmology (AAO); 2003. 21 p. [75 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1998 Sep (revised 2003)

GUIDELINE DEVELOPER(S)

American Academy of Ophthalmology - Medical Specialty Society

SOURCE(S) OF FUNDING

American Academy of Ophthalmology

GUIDELINE COMMITTEE

Preferred Practice Patterns Committee, Corneal/External Disease Panel

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Cornea/External Disease Panel Members: Alice Y. Matoba, MD (Chair); David J. Harris, Jr., MD; David M. Meisler, MD; Stephen C. Pflugfelder, MD; Christopher J. Rapuano, MD; Jayne S. Weiss, MD; David C. Musch, PhD, MPH (Methodologist)

Preferred Practice Patterns Committee Members: Joseph Caprioli, MD (Chair); J. Bronwyn Bateman, MD; Emily Y. Chew, MD; Douglas E. Gaasterland, MD; Sid Mandelbaum, MD; Samuel Masket, MD; Alice Y. Matoba, MD; Donald S. Fong, MD, MPH

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

The following authors have received compensation within the past 3 years up to and including June 2003 for consulting services regarding the equipment, process, or product presented or competing equipment, process, or product presented:

Jayne S. Weiss, MD: Alcon, Allergan - Reimbursement of travel expenses for presentation at meetings or courses.

Stephen C. Pflugfelder, MD: Allergan - Compensation received within the past three years for consulting services regarding the equipment, process, or product presented. Contribution to research or research funds.

Christopher J. Rapuano, MD: Allergan - Ad hoc consulting fees.

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: American Academy of Ophthalmology (AAO), Preferred Practice Patterns Committee, Cornea/External Disease. Dry eye syndrome. San Francisco (CA): American Academy of Ophthalmology (AAO); 1998. 18 p.

All Preferred Practice Patterns are reviewed by their parent panel annually or earlier if developments warrant.

GUIDELINE AVAILABILITY

Electronic copies: Available from the American Academy of Ophthalmology (AAO) Web site.

Print copies: Available from American Academy of Ophthalmology, P.O. Box 7424, San Francisco, CA 94120-7424; Phone: (415) 561-8540.

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

The following patient education brochures are available:

  • Dry eye. (1995)
  • Dry eye (Spanish-Ojo Seco) (2003)

Print copies: Available from the American Academy of Ophthalmology, P.O. Box 7424, San Francisco, CA 94120-7424; Phone: (415) 561-8540.

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC STATUS

This NGC summary was completed by ECRI on February 20, 1999. The information was verified by the guideline developer on April 23, 1999. This summary was updated by ECRI on April 9, 2004. The information was verified by the guideline developer on May 20, 2004.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Information about the content, ordering, and copyright permissions can be obtained by calling the American Academy of Ophthalmology at (415) 561-8500.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo